• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Smith & Nephew gets in on Michelson Diagnostics Series B round

Smith & Nephew gets in on Michelson Diagnostics Series B round

February 16, 2015 By Brad Perriello

Smith & Nephew gets in on Michelson Diagnostics Series B round

Smith & Nephew (FTSE:SN, NYSE:SNN) put down the cornerstone in the 1st tranche of Michelson Diagnostics‘ $3.8 million (£2.5 million) Series B round for its skin cancer detection device.

Kent, U.K.-based Michelson’s VivoSight device uses optical coherence tomography to generate images of tissues and vasculature beneath the skin. Smith & Nephew contributed $2.3 million (£1.5 million) to the Series B tranche, which also included new investor the Kent County Council, and existing backers.

Michelson said it hopes to raise a total of roughly $6.1 million (£4 million) with the round, expected to close "in the coming months." Proceeds are earmarked for expanding VivoSight’s footprint in Germany, where it’s approved to diagnose non-melanoma skin cancer, and for the launch of a next-generation device, according to a press release.

The company said it’s also planning to use the funds to complete a U.S. "biopsy avoidance" clinical trial and "explore further applications of the VivoSight system in areas such as wound care and dentistry.”

Smith & Nephew’s strategic initiatives senior vice president, Andrew Boyes, is slated to join Michelson’s board, according to the release. The companies said they plan to jointly explore "new indications for VivoSight such as the investigation of burn depth assessment."

"At Smith & Nephew we are keen to identify and develop innovative products which have the potential to significantly advance the way in which patients are diagnosed and treated. VivoSight fits that bill and we are very optimistic for its clinical and commercial prospects," Boyes said in prepared remarks.

"We are delighted to welcome Smith & Nephew both as a new investor and also to our board. Andrew Boyes brings a wealth of medical device development as well as industry-specific commercialisation expertise, which will prove invaluable through the next phase of growth at Michelson," chairman Brian Howlett added. "This is an exciting time for the company, as our 1st application of the VivoSight OCT system is rapidly gaining traction with commercial customers and key opinion leaders in Europe and the United States. Smith & Nephew joining the Series B round and taking a board seat not only validates our technology and the commercial impact that the VivoSight OCT system is demonstrating in NMSC imaging and diagnosis, but equally underscores the future potential of OCT imaging in other clinical modalities beyond dermatology."

Michelson raised a $3.2 million Series A2 round in January 2014.

Filed Under: Funding Roundup, News Well Tagged With: Dermatology, Michelson Diagnostics, Smith & Nephew

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy